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Among the discussed risk factors for high-titre inhibitor (HRI) development in patientswith hemophiliaA (HA) are high dose FVIII
replacement therapy and use of recombinant FVIII concentrates (rFVIII).The aim of this study was to evaluate the aforementioned
risk factors for HRI development in children with hemophilia A ≤2%. About 288 ascertained PUPs (Israel and Germany) were
followed after initial HAdiagnosis over 200 exposure days. Inhibitor-free survival, hazard ratios (HR), and 95% confidence intervals
(CIs) were calculated. Adjustment was performed for factor VIII concentrates, median single dose over the first three months of
treatment, first FVIII administration before the age of three months, presence of risk HA gene mutations, “intensive treatment
moments” and “year of birth” (proxy for different treatment periods). HRI occurred in 71/288 children (24.7%). In multivariate
analysis adjusted for “year of birth”, underlying risk gene mutations (HR/CI: 2.37/1.40–3.99), FVIII dose, measured per one IU
increase per kgbw (HR/CI: 1.05/1.04–1.07), and first FVIII administration before the age of three months showed a significant
impact on HR development. The risk of HRI development was similar for recombinant or plasmatic FVIII products. Children at
risk should be treated with carefully calculated lower dose regimens, adapted to individual bleeding situations.
1. Introduction
The development of problematic inhibitor antibodies against
factor VIII is the most important clinical challenge for
patients with hemophilia A (HA) and their treating physi-
cians [1]. Apart from endogenous risk factors for inhibitor
development, such as the underlying severity and the under-
lying hemophilia A—causing genemutation, particular inter-
ests have been focused on the role of risk factors, which
can be influenced by the treating institutions [2–5]. Among
treatment-related modifiable risks, the use of recombinant
FVIII (rFVIII) concentrates or high dose FVIII administra-
tion was controversially discussed as potential risk factors
for inhibitor development [2–6], and very recently data of
the RODIN study pointed out the unexpected finding that
the second generation rFVIII products compared to the third
generation FVIII concentrates are more immunogenic [7].
However, the paucity of the results of prospective randomized
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potentially relevant HA patients
Patients included in the study
aged neonate to ≤ 18 years
∑ = 314 [100%]
Electronic databases: ascertainment period 1980–2011
∑ = 288 out of 314 [91.7%]
Total HA patients ≤ 2%
n = 293
Excluded: ∑ = 21 [6.7%]
Reasons for exclusion
HA > 2–5%: n = 14
Pretreated: n = 7
Excluded: ∑ = 5 [1.6%]
Reasons for exclusion
Concomitant vWS: n = 2
Switch of FVIII concentrate: n = 3
Figure 1: Patient flow chart—inclusion and exclusion criteria are shown.
and adequately powered studies still suggest that other indi-
vidual patient level databases have to be analyzed to overcome
some of the controversies discussed.
The primary aim of the present international multicenter
study was to evaluate the aforementioned risk factors in an
independent cohort of children with severe and moderate-
severe hemophilia A, using baseline clinical and laboratory
variables. In addition, on an explorative basis the secondary
aimof this cohort studywas to proof the RODINhypothesis if
the use of second generation rFVIII products also has a higher
immunogenicity in our cohort.
2. Methods
2.1. Ethics. The present database study in consecutively re-
cruited pediatric patients with HA was performed in accor-
dance with the ethical standards laid down in a relevant ver-
sion of the 1964 Declaration of Helsinki and was approved by
the Medical Ethics Committee of the University of Münster,
Germany, and the institutional review boards of each study
center.
The present studywas reported in accordance to STROBE
guidelines for observational studies [8].
2.2. Inclusion/Exclusion Criteria. Inclusion and exclusion
criteria are shown in Figure 1. Previously untreated patients
(PUPs) with severe and moderately severe hemophilia A
(SHA: factor VIII activity ≤2% levels confirmed in at least
two independent plasma samples, or via the presence of a
high risk gene mutation [4]) aged neonate to ≤18 years at
the time of the first presentation in the study center, who
had been admitted to the University Children’s Hospitals of
Frankfurt, Halle, theMVZDuisburg, Kiel-Lubbock,Munich,
Münster, Germany, and the Hemophilia Treatment Center
Tel-Hashomer, Israel, at the first symptomatic onset of the
disease [9–12]. Patients born before 1980, pediatric patients
with HA additionally carrying von Willebrand disease, and
children with HA >2% were not included in this cohort
study. In addition, children pretreated with transfusion of
red blood cell concentrate, fresh frozen plasma before the
first administration of factor VIII concentrate, and patients
in whom a switch of factor concentrates during the study
period was performed were not enrolled. To avoid family
cluster effects in both countries, only the first HA patient who
presented for diagnosis at the treatment center was included
in the present study.
The final study cohort included 288 consecutively ascer-
tained PUPs with HA ≤2% who were followed over the
first 200 exposure days. Prior to enrollment into the Ger-
man database in each of the study centers, patients were
prospectively followed with respect to high-titer inhibitor
development. Prior to starting of prophylaxis, patients were
followedmonthly, and on prophylaxis clinical and laboratory
exploration was performed every three to four days until
exposure days (ED) 20, at least weekly until ED 50, followed
by monthly intervals thereafter in the majority of patients.
Twenty-three Israeli patients (8.1%) born between 2001 and
2009 were enrolled in parallel in the RODIN cohort [7] and
thus were excluded from the FVIII immunogenicity study
(secondary study aim). No further patient overlap has to be
reported.
2.3. Outcome Measures
2.3.1. Primary Study Aim. High-titer inhibitor-free survival
(IFS: first 200 ED) with respect to the discussed possible risk
factors.
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2.3.2. Secondary Study Aim. High-titer IFS with respect to
second generation rFVIII products compared to nonsecond
generation rFVIII products (first rFVIII) and pdFVIII.
2.4. Study Population. From 1980 to 2011, 314 consecutive
pediatric PUPs of Caucasian origin with a first symptomatic
onset of HA were ascertained (Figure 1).
2.5. Treatment. At the discretion of the participating cen-
ters and according to standard of care in the years of
patient enrollment, children were either treated with pri-
mary prophylaxis or with on-demand therapy followed by
secondary prophylaxis. Treatment in HA patients ≤2% was
started in the year of birth. For patients presentingwith severe
soft tissue bleeding at HA onset, an intensified treatment
protocol was introduced in the mid-1990s. These children
received a primary prophylactic treatment regimen follow-
ing the first symptomatic hemorrhage. In cases of trauma-
associated or large spontaneous hemorrhage, two-to-three
daily FVIII infusions were administered for a minimum
of five to seven days. The latter treatment episodes were
classified as “intensified treatment moments.”
2.6. Factor VIII Products. Apart from pdFVIII products with
and without vonWillebrand factor content (Beriate P, Factor
VIII SDH Intersero, Fanhdi, Haemoctin SDH, Hemophil M,
Humate P, Octanate), first generation rFVIII products (Helix-
ate/Kogenate: full-length FVIII, derived from baby hamster
kidney (BHK) cell lines, human albumin-stabilized; Recom-
binate: full-length FVIII, derived from Chinese hamster
ovary (CHO) cell lines, human albumin-stabilized) and sec-
ond generation rFVIII products (Helixate NexGen/Kogenate
FS: full-length FVIII, derived from BHK cells, sucrose-
stabilized; Refacto: B-domain-deleted FVIII, derived from
CHO cells, sucrose-stabilized) were administered due to the
discretion of the participating study centers (classification of
rFVIII products according to Josephson & Abshire 2004:13).
In this study cohort, the plasma-albumin-free third gener-
ation rFVIII Advate (full-length FVIII, derived from CHO
cells, trehalose-stabilized)was not included into the statistical
analysis because only two patients received this product.
2.7. Data Collection. Data include baseline factor VIII, factor
VIII genotype, age at first factor VIII infusion, factor VIII
brand, median single dose administered over the first three
months of treatment, frequency of weekly factor adminis-
tration, type of bleeding requiring intensive FVIII adminis-
tration (intensive treatment moments, such as intracerebral
hemorrhage or surgery) ethnicity, family history of inhibitor
development, year of birth, country of patient origin, results
of inhibitor measurements, and FVIII ED.
2.8. Laboratory Analysis. Plasma levels of factor VIII were
determined by one-stage clotting assays using standard lab-
oratory methods. Inhibitor testing was performed at least
monthly when on therapy using the Bethesda method or its
modification (Nijmegen). The lower detection limit was set
according to the inhibitor assay used in each study center, and
a peak inhibitor titer of >5 BU was defined as high responder
(HR). A positive HR inhibitor testing was stated when an HR
inhibitor wasmeasured at least in two independent follow-up
visits.
Prior to starting of prophylaxis, laboratory assessment of
inhibitor status was performed monthly, and on prophylaxis
laboratory assessment of inhibitor status was performed
every 4-5 ED until ED 20 and thereafter at least weekly
until ED 50, followed by monthly intervals thereafter in
the majority of patients. Protocols for inhibitor testing were
center specific and did not differ among patients treated with
various products.
2.9. Statistics. Statistical analyses were performed with the
MedCalc software (version 12.3.0) and the StatView 5 soft-
ware package (SAS Institute Inc.). Continuous variables
were presented as median (minimum–maximum) values and
evaluated by nonparametric statistics using the Wilcoxon-
Mann-Whitney 𝑈 test. Frequency distributions of adverse
outcome were compared with chi-square test or, if nec-
essary, Fisher’s exact test. In univariate analysis (logis-
tic regression), risk ratios were calculated as odds ratios
(ORs)/95%CIs. IFS, defined as the number of cumulative
ED until high-titer inhibitor development, was calculated
with Cox proportional-hazards regression, and hazard ratios
(HRs)/95% confidence intervals (CIs) were calculated addi-
tionally. Based on data obtained from (i) a literature research
[2–5, 7] and (ii) results from univariate analysis, the following
variables were incorporated in themultivariate analysis: first-
line use of plasma-derived (pd) or first generation rFVIII
products versus second generation rFVIII concentrates,
FVIII median single dose per IU/kg bodyweight (bw) applied
over the first three months of treatment (proxy for treatment
intensity), presence of risk gene mutations ((a) and (b): (a)
large deletion andnonsense⋙ (b) intron 22 inversion) versus
mutations with a lower risk ((c) and (d):≫ (c) missense > (d)
small deletions: 4), “presence versus absence” of intensified
treatment moments, and “early” (birth to three months of
age) versus “late” (>three months) administration of first
FVIII concentrate (variables were entered into the model if
𝑃 < 0.1 and removed from the model if 𝑃 ≥ 0.1). In
addition, since treatment regimens were modified over time,
the model was adjusted for different treatment periods using
“year of birth” as proxy. Adjusted risks were expressed as
hazard ratios (HRs) and 95%CIs. Using a rule of thumb for
proportional hazards analysis of including one independent
predictor for approximately 10 outcomes, we were able to
include six predictors in the model (71HR events : 14). The
criterion for statistical significance was set at alpha = 0.05. 𝑃
values are based on two-sided test.
3. Results
3.1. Study Population. Patient’ characteristics are shown in
Table 1. According to inclusion and exclusion criteria, the
final study cohort ascertained from 1980 to 2011 included
288 PUPs with HA ≤2% available for analysis. Children with
FVIII activities <1% did not differ significantly from patients
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Table 1: Characteristics of patients enrolled in the database.
Parameter of interest Total
𝑁 = 288
Years of birth 1980–2011
Ethnicity: caucasian (%) 100
Factor concentrates used (𝑛)
pdFVIII 177
rFVIII 111
Median (min–max) single dose FVIII
(IU/kg/bw) 35 (15–100)
Median (min–max) weekly substitution
intervals 3 (1–3)
Persistent high-titer inhibitor 71/288 (24.7%)
pdFVIII∗ 29/177 (16.38%)
rFVIII 41/111 (36.9%)
(i) First generation: 9/46 (19.5%)
CHO; full-length; human albumin 8/38 (12.5%)
BHK; full-length; human albumin 1/8 (21.0%)
(ii) Second generation: 32/63 (50.7%)
CHO; B-domain-deleted 5/14 (35.7%)
BHK; full-length; sucrose 27/49 (55.1%)
(iii) Third generation 1/2
CHO; full-length; trehalose 1/2 (50.0%)











BHK: baby hamster kidney; BU: Bethesda units; CHO: Chinese hamster
ovary; ICH: intracranial hemorrhage; min–max: minimum–maximum;
kg bw: kilogram bodyweight; pd: plasma derived; r: recombinant.
∗Beriate P (11/50: 22.0%); Hemophil M (8/39: 20.5%); Humate P (10/43:
23.0%).
with HA severity between 1% and 2% with respect to clinical
phenotypes or genotypes. The median (min–max) single
FVIII administered over the first three months of treatment,
themedianweekly substitution intervals on prophylaxis prior
to inhibitor development, and reasons for intensified FVIII
treatment are shown in Table 1. The distribution of factor
concentrates with respect to pdFVIII, first, second, and third
generation rFVIII products is shown in Table 1.
3.2. HRI Development. During the follow-up period (200
ED) in the HA patients investigated, the overall HRI status
was 71/288 (24.7%). HRI was diagnosed in 40 of 146 cases
(27.4%) with the intron 22 inversion, in 3 of 10 cases (30.0%)





























Figure 2: Cumulative inhibitor-free survival in children with severe
and moderate severe hemophilia A.
carrying large deletions, and in 5 of 16 patients with nonsense
mutations (31.3%). Furthermore, persistent HRI was found
in 8 of 39 children (20.5%) with missense mutations, in 5
of 34 individuals (14.7%) with small deletions, and in 10 of
43 children (23.3%) in which we did not find one of the
above listed variants so far.The corresponding IFS is shown in
Figure 2. In patients using second generation FVIII products,
the HR-inhibitor rate during the observation period was
significantly higher compared to (i) first generation products
(50.7%versus 19.5%;𝑃 = 0.002) and (ii) pdFVIII concentrates
(50.7% versus 16.4% 𝑃 < 0.001). Detailed information with
respect to the individual factor concentrates used is shown
in Table 1. Furthermore, we could not detect statistically
significant differences for HRI rates when comparing (i)
the use of CHO (full-length; human albumin stabilized)
with BHK (full-length; human albumin stabilized) products
(𝑃 = 1.0), (ii) B-domain deleted and full-length (sucrose-
stabilized) FVIII products (𝑃 = 0.32), and (iii) first
generation products compared with pdFVIII concentrates
(𝑃 = 0.77). In Table 2, the statistically significant associations
between HRI development and the possible predefined risk
factors calculated in univariate analysis are summarized.
3.3. Multivariate Analysis (Table 2). Cox proportional haz-
ards modeling, with the combined variables first-line use of
pd or first generation rFVIII products versus second gen-
eration rFVIII concentrates (pooling was performed based
on results of univariate analysis), FVIII median single dose
per IU/kg bodyweight (bw) applied over the first three
months of treatment, presence of a risk gene mutation [4],
presence versus absence of “intensified treatment moments,”
and “early” versus “late” first FVIII administration adjusted
for different treatment periods (year of birth) revealed that
the development of high titer inhibitors is of multifactorial
origin. Apart from the presence of risk gene mutations, the
use of high FVIII doses and the administration of “early”
FVIII factor concentrate before the age of three months
act as modifiers/confounders. Of note, subgroup analysis
performed in children with severe HA (𝑛 = 251) and in
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Table 2: (a) Univariate analyses. Odds ratios (ORs) and 95%
confidence intervals (CIs) are shown. (b) Multivariate analysis (Cox
proportional-hazards regression). Adjusted hazard ratios (HRs) and
95% confidence intervals (CIs) are shown.
(a)
Parameter investigated Odds ratio (95% CIs)
Comparator pdFVIII∗
First generation rFVIII (all products) 1.24 (0.54–2.84)
CHO; full-length, human albumin 0.9 (0.39–2.19)
BHK; full-length; human albumin 1.07 (0.45–2.53)
Second generation rFVIII (all products) 2.98 (1.71–5.20)
BHK; full-length sucrose 6.26 (3.14–12.4)
CHO; B-domain deleted 2.83 (0.88–9.07)
Comparator 1 IU/kg bw
Median single FVIII dose increase per
one IU/kg bw 1.07 (1.05–1.09)
Comparator “late” FVIII administration
versus
“early” FVIII administration 3.17 (1.83–5.51)
Comparator: intensified treatment
moments “absent”
Intensified treatment moments present 2.86 (1.18–6.96)
Comparator : risk gene mutation “absent”
High risk gene mutation present 5.45 (3.04–9.76)
Comparator “year of birth” 1 year
Increase per birth year 1.10 (1.06–1.15)
kg bw: kilogram bodyweight; ∗exclusion of 23 Israeli children (RODIN
overlap).
(b)
Parameter investigated Hazard ratios (95% CIs)
Comparator pdFVIII/first generation
FVIII
Second generation rFVIII 1.37 (0.7–2.68)
Comparator 1 IU/kg bw
Median single FVIII dose increase per
one IU/kg bw 1.05 (1.04–1.07)
Comparator “late” FVIII administration
versus
“early” FVIII administration 1.97 (1.15–3.4)
Comparator: intensified treatment
moments “absent”
Intensified treatment moments present 1.19 (0.58–2.45)
Comparator: risk gene mutation
“absent”
High risk gene mutation present 2.37 (1.40–3.99)
Comparator “year of birth” 1 year
Increase per birth year 1.08 (1.03–1.13)
kg bw: kilogram bodyweight.
children derived from Germany (𝑛 = 200) did not alter
the results obtained from the pooled study group including
patients with severe and moderate-severe HA (Supplemen-
tary Table 1) (See Supplementary Material available online
at http://dx.doi.org/10.1155/2013/901975). In this multivariate
analysis, we could no longer find significant risk associations
between inhibitor development and the different FVIII prod-
ucts administered or the presence of intensified treatment
moments. In addition, when comparing pooled rFVIII prod-
ucts with pdFVIII concentrates, the adjusted HR (95%CIs)
was 1.1 (0.6–1.96) and 1.21 (0.58–2.51)when comparing pooled
second rFVIII with pdFVIII concentrates.
4. Discussion
The data reported in the present study underline the under-
standing that HRI development in children with HA ≤2% is
of multifactorial origin [2–7, 13–15].The cumulative HRI rate
of 24.7% is within the range expected for database studies
[16]. As shown in the subgroup analysis, data in children
with severe HA and data obtained from German HA patients
only did not substantially alter the results. As secondary
study aim we evaluated the recently discussed unexpected
observation that second generation rFVIII concentrations are
more immunogenic [7]. We investigated the risk of inhibitor
development with respect to the use of first versus second
generation rFVIII concentrates and subsequently the role
of second rFVIII versus pdFVIII products. After exclusion
of 23HA patients from Israel who have been enrolled in
parallel into the RODIN study, the higher immunogenicity
of second versus first generation rFVIII products and second
generation versus pdFVIII concentrates remains statistically
significant. We could not detect statistically significant dif-
ferences between B-domain-deleted and full-length (sucrose-
stabilized) FVIII products, nor could we find differences
in immunogenicity when comparing the individual first
generation FVIII with pdFVIII concentrates. Thus, in the
final multivariate analysis we grouped B-domain-deleted
with second generation FVIII products and compared this
entity with first generation and pdFVIII products. In this
multivariate analysis, further controlling for potentially risk
factors like “intensive treatment moments” and “early” versus
“late” first FVIII administration adjusted for different treat-
ment periods (variable “year of birth”), we could demonstrate
that, apart from the genetic HA background, given by the
underlying gene mutation [4], the FVIII administration
given before the age of three months (variable “early” versus
“late” first FVIII administration) did play an independent
role in the HRI development in children ascertained from
Israel and Germany: when we compared the patients treated
with doses between 15 IU/kg and 100 IU/kg, we saw that
for every 1 IU/Kg added to dosage, the risk for inhibitor
occurrence increased. Thus, when substituting a 6-week-old
male (bodyweight five kg) carrying anHA riskmutation with
a complete vial of 250 IU of factor FVIII concentrate, that
is, 50 IU/kg body weight, the risk to develop persistent HRI
is twofold higher compared to an individual using a dose of
25 IU/kg bodyweight (50%mL of a 250mL vial, littering the
remaining 50%).The latter results reflect the real life situation
in children with HA. The adjustment variable “year of birth”
demonstrated the influence of different treatment periods on
HRI development: when we compared patients born between
1980 and 2011, we saw that, for every 1 year added to 1980,
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the risk for inhibitor occurrence increased. As in the RODIN
cohort and our recently published meta-analysis, the risk of
high-titer inhibitor development was similar for rFVIII and
pdFVIII products [6, 7]. Thus, in light of the recent results
of the RODIN study, the positive association between HRI
development and second generation FVIII products detected
in univariate analysis may be discussed as a chance finding
rather than a causal effect.
In the present database study, we were unable to inves-
tigate the role of third generation rFVIII concentrates since
only two patients received the CHO cell-line derived plasma-
albumin-free trehalose-stabilized product in this study. How-
ever, the interpretation of less immunogenicity of this
plasma-albumin-free product in children with severe or
moderate-severe HA should be stated with caution and
should be restricted to the recently published RODIN cohort
[7], which did not include patients born in 2011.
Having overcome the problems of transmission of viral
diseases, the development of inhibitors currently repre-
sents the most challenging issue in patient management of
hemophilia today [13, 17]. One important question remains
wether different treatment regimens may influence inhibitor
development [2–5, 7]. While waiting for prospective data
derived from individual birth cohorts to become available
[16] and being aware of the limitations of retrospective
studies, our aim was to evaluate known risk factors for
inhibitor development in severe and moderate-severe HA
children on an individual patient-based level. Using baseline
clinical and laboratory variables, we have addressed the
question of inhibitor development in analyzing data from
Israel and Germany, which were collected consecutively over
the past thirty years from hemophilia treatment centers [9–
12, 15], in which in the majority the same leading physician
teams were responsible for patient care. In each of the study
centers, patients were prospectively followed with respect to
HRI development.
As in the RODIN study, the approach of this multicenter
database study has several limitations: in addition to the
limitations discussed by Iorio and coworkers [18] and Kessler
and Iorio [19] following the recent report of the RODIN
study, (i) the multivariate analysis in the present cohort was
performed in Caucasian children derived from Israel and
Germany enrolled between 1980 and 2011. As in the RODIN
study, this includes a heterogeneous patient population with
respect to year of birth, study center, and type of FVIII prod-
ucts. In addition, the pooled patient cohort investigated here
is a nonconcurrent cohort study, including inherent biases
known for retrospective data collection. However, since in
the participating study centers all patients were followed
up prospectively with respect to the study endpoint “HRI
development,” without differences among patients treated
with various FVIII products, reporting, recall, or selection
bias is unlikely. (ii) Additionally, the risk profile presented
here cannot be generalized to other ethnic groups and
needs to be investigated in external non-Israeli/non-German
cohorts. (iii)The long recruitment period of this study results
in a substantial heterogeneity of treatment strategies and
differences in factor VIII products. However, since data
were adjusted for different study periods including treatment
strategies (variable “year of birth”) and since inhibitor rates
were found in line with recently published literature [3–
5, 7], selection or reporting bias seems unlikely. As a further
limitation, results presented here are restricted to (iv) the
development of high responding inhibitors and (v) patients
with severe and moderate-severe haemophilia A. Since the
number of children treated with each factor product is small,
(vi) results of the present cohort study have to be interpreted
with caution.
In conclusion, in this multicenter international cohort
study we evaluated risk factors, modifiers, and confounders
which increase the risk for symptomatic high-titer inhibitor
development during hemophilia treatment protocols for
children. Until more data are available, children with HA at
risk should be treated with rFVIII or pdFVIII concentrates
with carefully calculated lower dose regimens, adapted to the
individual bleeding situation.
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